D-1289-2014 Class II Terminated

Recalled by AbbVie Inc — North Chicago, IL

FDA drug recall D-1289-2014 was initiated by AbbVie Inc on Mar 10, 2014 and is designated Class II. Reason for recall: Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device. The recall status is terminated (terminated Jun 22, 2016). Affected quantity: 12 kits.

Recall details

Product Type
Drugs
Report Date
May 7, 2014
Initiation Date
Mar 10, 2014
Termination Date
Jun 22, 2016
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12 kits

Product description

LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension) Single Dose Administration Kit with prefilled dual-chamber syringe, 11.25 mg for 3-month administration, Rx only, Manufactured for: AbbVie Inc., North Chicago, IL 60064; by: Takeda Pharmaceutical Company Limited, Osaka, Japan 540-8645; NDC 0074-3779-03, UPC 3 00743 77903 5.

Reason for recall

Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot #:1013566, Exp 12/08/16

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1289-2014
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for AbbVie Inc? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-1289-2014. Report a data issue: hello@regdatalab.com.